Syros Pharmaceuticals Stock Performance
| SYRS Stock | USD 0.24 0.01 4.00% |
The entity has a beta of 2.73, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Syros Pharmaceuticals will likely underperform. At this point, Syros Pharmaceuticals has a negative expected return of -1.08%. Please make sure to validate Syros Pharmaceuticals' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Syros Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Syros Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:10 | Last Split Date 2022-09-19 |
1 | Disposition of 10000 shares by Quirk Gerald E of Syros Pharmaceuticals subject to Rule 16b-3 | 09/30/2024 |
2 | Disposition of 6301 shares by Roth David of Syros Pharmaceuticals at 2.22 subject to Rule 16b-3 | 10/18/2024 |
3 | Disposition of 17000 shares by Kristin Stephens of Syros Pharmaceuticals subject to Rule 16b-3 | 10/31/2024 |
4 | Acquisition by Fanucci Marsha of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
5 | Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression | 11/12/2024 |
6 | TD Cowen downgrades Syros Pharma stock to Hold on trial failure | 11/13/2024 |
7 | Avidity Partners Management LPs Strategic Acquisition in Syros Pharmaceuticals Inc | 11/15/2024 |
8 | Syros Pharmaceuticals announces major company changes | 11/18/2024 |
9 | Disposition of 46657 shares by Quirk Gerald E of Syros Pharmaceuticals at 0.2212 subject to Rule 16b-3 | 11/19/2024 |
10 | Syros Pharmaceuticals CEO Chee Conley sells shares worth 26,932 | 11/20/2024 |
11 | Disposition of 134713 shares by Simonian Nancy A of Syros Pharmaceuticals at 0.2653 subject to Rule 16b-3 | 11/25/2024 |
12 | Disposition of 37070 shares by Simonian Nancy A of Syros Pharmaceuticals at 0.2702 subject to Rule 16b-3 | 12/02/2024 |
13 | Nancy Simonian sells shares in Syros Pharmaceuticals for 10,016 | 12/04/2024 |
14 | Acquisition by Richard Young of 2667 shares of Syros Pharmaceuticals subject to Rule 16b-3 | 12/06/2024 |
| Begin Period Cash Flow | 170.6 M |
Syros |
Syros Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 195.00 in Syros Pharmaceuticals on September 13, 2024 and sell it today you would lose (171.00) from holding Syros Pharmaceuticals or give up 87.69% of portfolio value over 90 days. Syros Pharmaceuticals is currently does not generate positive expected returns and assumes 14.3631% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Syros, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Syros Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syros Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Syros Pharmaceuticals, and traders can use it to determine the average amount a Syros Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0754
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SYRS |
Estimated Market Risk
| 14.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Syros Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Syros Pharmaceuticals by adding Syros Pharmaceuticals to a well-diversified portfolio.
Syros Pharmaceuticals Fundamentals Growth
Syros Stock prices reflect investors' perceptions of the future prospects and financial health of Syros Pharmaceuticals, and Syros Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Syros Stock performance.
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (288.92) % | ||||
| Current Valuation | 8.5 M | ||||
| Shares Outstanding | 26.83 M | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 10.65 X | ||||
| Price To Sales | 16.96 X | ||||
| Revenue | 9.94 M | ||||
| Gross Profit | 14.88 M | ||||
| EBITDA | (157.19 M) | ||||
| Net Income | (164.57 M) | ||||
| Cash And Equivalents | 244.48 M | ||||
| Cash Per Share | 12.09 X | ||||
| Total Debt | 62.08 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 6.57 X | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (109.71 M) | ||||
| Earnings Per Share | (3.07) X | ||||
| Market Capitalization | 6.55 M | ||||
| Total Asset | 168.17 M | ||||
| Retained Earnings | (722.81 M) | ||||
| Working Capital | 108.3 M | ||||
| Current Asset | 85.51 M | ||||
| Current Liabilities | 9.57 M | ||||
About Syros Pharmaceuticals Performance
Assessing Syros Pharmaceuticals' fundamental ratios provides investors with valuable insights into Syros Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Syros Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (9.88) | (9.38) |
Things to note about Syros Pharmaceuticals performance evaluation
Checking the ongoing alerts about Syros Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Syros Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Syros Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syros Pharmaceuticals has high historical volatility and very poor performance | |
| Syros Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Syros Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.94 M. Net Loss for the year was (164.57 M) with profit before overhead, payroll, taxes, and interest of 14.88 M. | |
| Syros Pharmaceuticals currently holds about 244.48 M in cash with (109.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Syros Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Nancy Simonian sells shares in Syros Pharmaceuticals for 10,016 |
- Analyzing Syros Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Syros Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Syros Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Syros Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Syros Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Syros Pharmaceuticals' stock. These opinions can provide insight into Syros Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.